These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 21708958)

  • 1. The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy.
    Fu T; He Q; Sharma P
    Cancer Res; 2011 Aug; 71(16):5445-54. PubMed ID: 21708958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.
    Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H
    Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inducible costimulator ligand regulates bleomycin-induced lung and skin fibrosis in a mouse model independently of the inducible costimulator/inducible costimulator ligand pathway.
    Tanaka C; Fujimoto M; Hamaguchi Y; Sato S; Takehara K; Hasegawa M
    Arthritis Rheum; 2010 Jun; 62(6):1723-32. PubMed ID: 20191584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.
    Sundstedt A; Celander M; Eriksson H; Törngren M; Hedlund G
    J Immunother; 2012 May; 35(4):344-53. PubMed ID: 22495392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
    Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
    Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4 T cells require ICOS-mediated PI3K signaling to increase T-Bet expression in the setting of anti-CTLA-4 therapy.
    Chen H; Fu T; Suh WK; Tsavachidou D; Wen S; Gao J; Ng Tang D; He Q; Sun J; Sharma P
    Cancer Immunol Res; 2014 Feb; 2(2):167-76. PubMed ID: 24778280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade.
    Guillonneau C; Aubry V; Renaudin K; Séveno C; Usal C; Tezuka K; Anegon I
    Transplantation; 2005 Aug; 80(4):546-54. PubMed ID: 16220623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inducible costimulator (ICOS) blockade inhibits accumulation of polyfunctional T helper 1/T helper 17 cells and mitigates autoimmune arthritis.
    Frey O; Meisel J; Hutloff A; Bonhagen K; Bruns L; Kroczek RA; Morawietz L; Kamradt T
    Ann Rheum Dis; 2010 Aug; 69(8):1495-501. PubMed ID: 20498202
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Th1 cytokine responses fail to effectively control Chlamydia lung infection in ICOS ligand knockout mice.
    Kadkhoda K; Wang S; Joyee AG; Fan Y; Yang J; Yang X
    J Immunol; 2010 Apr; 184(7):3780-8. PubMed ID: 20190137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade.
    Guillonneau C; Aubry V; Renaudin K; Séveno C; Usal C; Tezuka K; Anegon I
    Transplantation; 2005 Jul; 80(2):255-63. PubMed ID: 16041272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD28/CTLA-4--CD80/CD86 and ICOS--B7RP-1 costimulatory pathway in bronchial asthma.
    Chen YQ; Shi HZ
    Allergy; 2006 Jan; 61(1):15-26. PubMed ID: 16364152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inducible co-stimulatory molecule ligand is protective during the induction and effector phases of crescentic glomerulonephritis.
    Odobasic D; Kitching AR; Semple TJ; Holdsworth SR
    J Am Soc Nephrol; 2006 Apr; 17(4):1044-53. PubMed ID: 16540559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems.
    Gregor PD; Wolchok JD; Ferrone CR; Buchinshky H; Guevara-Patiño JA; Perales MA; Mortazavi F; Bacich D; Heston W; Latouche JB; Sadelain M; Allison JP; Scher HI; Houghton AN
    Vaccine; 2004 Apr; 22(13-14):1700-8. PubMed ID: 15068853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.
    Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
    Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical role of inducible costimulator signaling in the development of arteriosclerosis.
    Kosuge H; Suzuki J; Haraguchi G; Koga N; Maejima Y; Inobe M; Isobe M; Uede T
    Arterioscler Thromb Vasc Biol; 2006 Dec; 26(12):2660-5. PubMed ID: 16990558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Importance of the inducible costimulator molecule for the induction of allergic immune responses and its decreased expression on T helper cells after venom immunotherapy.
    Bellinghausen I; Klostermann B; Böttcher I; Knop J; Saloga J
    Immunology; 2004 May; 112(1):80-6. PubMed ID: 15096187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of ICOS-B7RP-1 costimulation in acute and chronic allograft rejection.
    Ozkaynak E; Gao W; Shemmeri N; Wang C; Gutierrez-Ramos JC; Amaral J; Qin S; Rottman JB; Coyle AJ; Hancock WW
    Nat Immunol; 2001 Jul; 2(7):591-6. PubMed ID: 11429542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelial inducible costimulator ligand expression is increased during human cardiac allograft rejection and regulates endothelial cell-dependent allo-activation of CD8+ T cells in vitro.
    Klingenberg R; Autschbach F; Gleissner C; Giese T; Wambsganss N; Sommer N; Richter G; Katus HA; Dengler TJ
    Eur J Immunol; 2005 Jun; 35(6):1712-21. PubMed ID: 15864782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
    Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B7+ iris pigment epithelial cells convert T cells into CTLA-4+, B7-expressing CD8+ regulatory T cells.
    Sugita S; Keino H; Futagami Y; Takase H; Mochizuki M; Stein-Streilein J; Streilein JW
    Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5376-84. PubMed ID: 17122127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.